Paul Capital Partners, a private equity secondary and fund of funds specialist, has made a significant move in its third line of business through the securitisation of a collection of biopharmaceutical, medical device and diagnostic royalties.
The new securities, backed by Royalty Securitization Trust I, are being issued as $228.9
